Document:

EX-10.1

 Exhibit 10.1 

REGISTRATION RIGHTS AGREEMENT 
 THIS REGISTRATION
RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of June 19, 2014, by and among Actavis Funding SCS, a société en commandite simple organized under the laws of the Grand Duchy of Luxembourg, having
its registered office at 46A, avenue J.F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg (“Luxembourg”) registered with the Luxembourg Register of Commerce and Companies under number B187.310 and having a share capital of
$20,000 (the “Issuer”), Actavis Capital S.à r.l., a private limited liability company (société à responsabilité limitée) incorporated under the laws of the Grand Duchy of Luxembourg, having
its registered office at 46A, avenue J.F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg registered with the Luxembourg Register of Commerce and Companies under number B178.410 and having a share capital of $171,656 (“Actavis
Capital”), Actavis, Inc., a Nevada corporation (“Actavis”), Warner Chilcott Limited, a Bermuda Company (“Intermediate Parent” and collectively with Actavis Capital and Actavis, the
“Guarantors”) and Merrill Lynch, Pierce, Fenner & Smith Incorporated, Mizuho Securities USA Inc. and Wells Fargo Securities, LLC as representatives (the “Representatives”) of the several initial purchasers
listed on Schedule A hereto (collectively, the “Initial Purchasers”). 
 This Agreement is made pursuant to the Purchase
Agreement dated as of June 10, 2014 (the “Purchase Agreement”), between the Issuer, the Guarantors and the Representatives, on behalf of the Initial Purchasers, which provides for the sale by the Issuer to the Initial
Purchasers of an aggregate of $500,000,000 principal amount of the Issuer’s 1.300% Notes due 2017 (the “2017 Notes”), an aggregate of $500,000,000 principal amount of the Issuer’s 2.450% Notes due 2019 (the “2019
Notes”), an aggregate of $1,200,000,000 principal amount of the Issuer’s 3.850% Notes due 2024 (the “2024 Notes”) and an aggregate of $1,500,000,000 principal amount of the Issuer’s 4.850% Notes due 2044 (the
“2044 Notes”) in each case fully and unconditionally guaranteed by the Guarantors (the “Guarantees”). As used herein, “Securities” shall mean the 2017 Notes, the 2019 Notes, the 2024 Notes and the
2044 Notes and the Guarantees thereof, as individual series of notes and not collectively. In order to induce the Initial Purchasers to enter into the Purchase Agreement and for good and valuable consideration to the Holders of the Securities, the
Issuer has agreed to provide to the Initial Purchasers and their direct and indirect transferees the registration rights set forth in this Agreement. The execution and delivery of this Agreement is a condition to the closing under the Purchase
Agreement. 
 In consideration of the foregoing, the parties hereto agree as follows: 

1. Definitions. 
 As used
in this Agreement, the following capitalized defined terms shall have the following meanings: 
 “1933 Act” shall mean the
Securities Act of 1933, as amended from time to time. 
 “1934 Act” shall mean the Securities Exchange Act of 1934, as
amended from time to time. 
 “2017 Notes” shall have the meaning set forth in the preamble. 

“2019 Notes” shall have the meaning set forth in the preamble. 

 “2024 Notes” shall have the meaning set forth in the preamble. 

“2044 Notes” shall have the meaning set forth in the preamble. 

“Beneficial Owner” has the meaning assigned to such term in Rule 13d-3 and Rule 13d-5 under the 1934 Act, except
that in calculating the beneficial ownership of any particular “person” (as that term is used in Section 13(d)(3) of the 1934 Act), such “person” will be deemed to have beneficial ownership of all securities that such
“person” has the right to acquire by conversion or exercise of other securities, whether such right is currently exercisable or is exercisable only upon the occurrence of a subsequent condition. The terms “Beneficially Owns” and
“Beneficially Owned” will have correlative meanings. 
 “Closing Date” shall mean the Closing Date as defined in
the Purchase Agreement. 
 “Exchange Dates” shall have the meaning set forth in Section 2(a)(ii) hereof. 

“Exchange Offer” shall mean an exchange offer by the Issuer of Exchange Securities of a series for Registrable Securities of
the applicable series pursuant to Section 2(a) hereof. 
 “Exchange Offer Registration” shall mean a registration under
the 1933 Act effected pursuant to Section 2(a) hereof. 
 “Exchange Offer Registration Statement” shall mean an
exchange offer registration statement on Form S-4 (or, if applicable, on another appropriate form) and all amendments and supplements to such registration statement, in each case including the Prospectus contained therein, all exhibits thereto and
all material incorporated by reference therein. 
 “Exchange Securities” shall mean four series of securities, each issued
by the Issuer under the Indenture containing terms identical to the corresponding series of Securities (except that (i) interest thereon shall accrue from the last date on which interest was paid on the Securities of such series or, if no such
interest has been paid, from June 19, 2014 and (ii) the Exchange Securities will not contain restrictions on transfer) and to be offered to Holders of the applicable series of Securities in exchange for Securities of such series pursuant
to the Exchange Offer. 
 “Free Writing Prospectus” shall mean each free writing prospectus (as defined in Rule 405 under
the 1933 Act) prepared by or on behalf of the Issuer or used by the Issuer in connection with a Shelf Registration. 

“Holder” shall mean, for each series of Registrable Securities, the Initial Purchasers, for so long as they own any
Registrable Securities of such series, and each of their respective successors, assigns and direct and indirect transferees who become registered owners of Registrable Securities of such series under the Indenture, including any Person that acquired
any Registrable Securities of such series prior to the date hereof; provided that for purposes of Sections 4 and 5 hereof, the term “Holder” shall include Participating Broker-Dealers. 

  
 2 

 “Indenture” shall mean, the Indenture, dated as of June 19, 2014, by and
among the Issuer, the Guarantors and Wells Fargo Bank, National Association, as trustee (the “Trustee”), pursuant to which the Securities are to be issued, as such Indenture is amended or supplemented from time to time in accordance
with the terms thereof. 
 “Initial Purchasers” shall have the meaning set forth in the preamble. 

“Issuer” shall have the meaning set forth in the preamble. 

“Majority Holders” shall mean, for any series of Registrable Securities, the Holders of a majority of the aggregate principal
amount of outstanding Registrable Securities of such series; provided that whenever the consent or approval of Holders of a specified percentage of Registrable Securities of such series is required hereunder, Registrable Securities of such
series held by the Issuer or any of its affiliates (as such term is defined in Rule 405 under the 1933 Act) (other than the Initial Purchasers or subsequent Holders of Registrable Securities of such series if such subsequent Holders are deemed to be
such affiliates solely by reason of their holding of such Registrable Securities) shall not be counted in determining whether such consent or approval was given by the Holders of such required percentage or amount of such series. 

“Merger” shall mean the merger of Forest Laboratories, Inc. into Actavis plc pursuant to that certain sale and purchase
agreement and plan of merger, dated February 17, 2014 among Actavis plc, Tango US Holdings Inc., Tango Merger Sub 1 LLC and Tango Merger Sub 2 LLC. 

“Outside Date” shall mean, initially August 17, 2014, as the same may be extended by up to an additional four months in
certain circumstances as described in that certain sale and purchase agreement and plan of merger, dated February 17, 2014 among Actavis plc, Tango US Holdings Inc., Tango Merger Sub 1 LLC, Tango Merger Sub 2 LLC. 

“Participating Broker-Dealer” shall have the meaning set forth in Section 4(a) hereof. 

“Person” shall mean an individual, partnership, limited liability company, corporation, trust or unincorporated organization,
or a government or agency or political subdivision thereof. 
 “Prospectus” shall mean the prospectus included in a
Registration Statement, including any preliminary prospectus, and any such prospectus as amended or supplemented by any prospectus supplement, including a prospectus supplement with respect to the terms of the offering of any portion of the
Registrable Securities covered by a Shelf Registration Statement, and by all other amendments and supplements to such prospectus, and in each case including all material incorporated or deemed by securities laws to be incorporated by reference
therein. 
 “Purchase Agreement” shall have the meaning set forth in the preamble. 

“Registrable Securities” shall mean the Securities; provided, however, that the Securities of a series shall
cease to be Registrable Securities (i) when a Registration Statement with respect to such Securities shall have been declared effective under the 1933 Act and either 

  
 3 

 
(a) such Securities are exchanged for Exchange Securities of the applicable series in the Exchange Offer or (b) such Securities were not tendered by the Holder thereof in the Exchange Offer,
except as a result of Section 2(b)(iii) below (provided that the Exchange Offer was conducted in accordance with the terms of this Agreement, including with respect to periods during which the Securities may be exchanged), (ii) when a
Shelf Registration Statement with respect to such Securities shall have been declared effective under the 1933 Act and such Securities shall have been disposed of pursuant to such Registration Statement, (iii) when such Securities have been
sold to the public pursuant to Rule 144 (or any similar provision then in force, but not Rule 144A) under the 1933 Act or (iv) when such Securities shall have ceased to be outstanding. 

“Registration Default” shall have the meaning set forth in Section 2(d) hereof. 

“Registration Expenses” shall mean any and all expenses incident to performance of or compliance by the Issuer with this
Agreement, including without limitation: (i) all SEC, stock exchange or Financial Industry Regulatory Authority registration and filing fees, (ii) all fees and expenses incurred in connection with compliance with state securities or blue
sky laws (including reasonable fees and disbursements of counsel for any underwriters or Holders in connection with blue sky qualification of any of the Exchange Securities or Registrable Securities), (iii) all expenses of any Persons in
preparing or assisting in preparing, word processing, printing and distributing any Registration Statement, any Prospectus, any amendments or supplements thereto, any underwriting agreements, securities sales agreements and other documents relating
to the performance of and compliance with this Agreement, (iv) all rating agency fees, (v) all fees and disbursements relating to the qualification of the Indenture under applicable securities laws, (vi) the fees and disbursements of
the Trustee and its counsel and any depositary for book-entry Securities, (vii) the fees and disbursements of counsel for the Issuer and, in the case of a Shelf Registration Statement, the reasonable fees and disbursements of one counsel for
the Holders (which counsel shall be selected by the Majority Holders and which counsel may also be counsel for the Initial Purchasers) and (viii) the fees and disbursements of the independent public accountants of the Issuer (and, if necessary,
any other certified public accountant of any parent of the Issuer, or of any business acquired by the Issuer for which financial statements and financial data are or are required to be included in the Registration Statement), including the expenses
of any special audits or “cold comfort” letters required by or incident to such performance and compliance, but excluding fees and expenses of counsel to the underwriters (other than fees and expenses set forth in clause (ii) above)
or the Holders and underwriting discounts and commissions and transfer taxes, if any, relating to the sale or disposition of Registrable Securities by a Holder. 

“Registration Statement” shall mean any registration statement of the Issuer that covers any of the Exchange Securities or
Registrable Securities pursuant to the provisions of this Agreement and all amendments and supplements to any such Registration Statement, including post-effective amendments, in each case including the Prospectus contained therein, all exhibits
thereto and all material incorporated or deemed by securities laws to be incorporated by reference therein. 
 “SEC” shall
mean the Securities and Exchange Commission. 

  
 4 

 “Securities” shall have the meaning set forth in the preamble. 

“Shelf Registration” shall mean a registration effected pursuant to Section 2(b) hereof. 

“Shelf Registration Statement” shall mean a “shelf” registration statement of the Issuer filed pursuant to the
provisions of Section 2(b) hereof on an appropriate form under 1933 Act relating to the offer and sale of all of the Registrable Securities (but no other securities unless approved by the Holders whose Registrable Securities are covered by such
Shelf Registration Statement) under Rule 415 under the 1933 Act, or any similar rule that may be adopted by the SEC, and all amendments and supplements to such registration statement, including post-effective amendments, in each case including the
Prospectus contained therein, all exhibits thereto and all material incorporated or deemed by securities law to be incorporated by reference therein. 

“Staff” shall have the meaning set forth in Section 4(a) hereof. 

“Trustee” shall mean the trustee with respect to the Securities under the Indenture. 

“Underwriter” shall have the meaning set forth in Section 3 hereof. 

“Underwritten Registration” or “Underwritten Offering” shall mean a registration in which Registrable
Securities are sold to an Underwriter for reoffering to the public. 
 2. Registration Under the 1933 Act. 

(a) To the extent not prohibited by any applicable law or applicable interpretation of the Staff, the Issuer and the Guarantors shall
(i) file an Exchange Offer Registration Statement covering the offer by the Issuer to the Holders of each series of Registrable Securities to exchange all of the Registrable Securities of such series for Exchange Securities of the applicable
series and (ii) use their commercially reasonable efforts to have the Exchange Offer Registration Statement declared effective by the SEC as promptly as practicable after such Registration Statement has been filed. The Issuer and the Guarantors
shall commence the Exchange Offer promptly after the Exchange Offer Registration Statement has been declared effective by the SEC and keep the Exchange Offer open for not less than 20 business days (or longer if required by applicable law) after the
date notice of the Exchange Offer is mailed to Holders of the Securities. The Issuer and the Guarantors shall commence the Exchange Offer by mailing the related exchange offer Prospectus and accompanying documents to each Holder stating, in addition
to such other disclosures as are required by applicable law: 
 (i) that the Exchange Offer is being made pursuant to this Agreement and that
all Registrable Securities validly tendered will be accepted for exchange; 
 (ii) the dates of acceptance for exchange (which shall be a
period of at least 20 business days from the date such notice is mailed) (the “Exchange Dates”); 
 (iii) that any
Registrable Security not tendered will remain outstanding and continue to accrue interest, but will not retain any rights under this Agreement; 

  
 5 

 (iv) that Holders electing to have a Registrable Security exchanged pursuant to the Exchange
Offer will be required to (A) surrender such Registrable Security, together with the enclosed letters of transmittal, to the institution and at the address specified in the notice prior to the close of business on the last Exchange Date or
(B) effect such exchange otherwise in compliance with the applicable procedures of the depositary for such Registrable Security; provided, however, that, if any of the Registrable Securities are in book-entry form, such Prospectus
and accompanying documents shall also specify how the surrender is to be effected in accordance with applicable book-entry procedures; and 

(v) that Holders will be entitled to withdraw their election, not later than the close of business on the last Exchange Date, by sending to the
institution and at the address specified in the notice a telegram, telex, facsimile transmission or letter setting forth the name of such Holder, the principal amount of Registrable Securities delivered for exchange and a statement that such Holder
is withdrawing his election to have such Securities exchanged. 
 As soon as practicable after the last Exchange Date, the Issuer shall: 

(i) accept for exchange Registrable Securities or portions thereof tendered and not validly withdrawn pursuant to the Exchange Offer; and 

(ii) deliver, or cause to be delivered, to the Trustee for cancellation all Registrable Securities or portions thereof so accepted for exchange
by the Issuer and issue, and cause the Trustee to promptly authenticate and mail to each Holder, an Exchange Security of the applicable series equal in principal amount to the principal amount of the Registrable Securities surrendered by such
Holder; provided that if any of the Registrable Securities are in book-entry form, the Issuer shall, in co-operation with the Trustee, effect the exchange of Registrable Securities in accordance with applicable book-entry procedures. 

The Issuer shall use its commercially reasonable efforts to complete the Exchange Offer as provided above and shall comply with the applicable requirements of
the 1933 Act, the 1934 Act and other applicable laws and regulations in connection with the Exchange Offer. The Exchange Offer shall not be subject to any conditions, other than that the Exchange Offer does not violate applicable law or any
applicable interpretation of the Staff. The Issuer shall, if requested by the Initial Purchasers, use its reasonable efforts to inform the Initial Purchasers of the names and addresses of the Holders to whom the Exchange Offer is made, and the
Initial Purchasers shall have the right, subject to applicable law, to contact such Holders and otherwise facilitate the tender of Registrable Securities in the Exchange Offer. 

(b) In the event that (i) the Issuer is not permitted to consummate the Exchange Offer provided for in Section 2(a) above because
the Exchange Offer is not permitted by applicable law or any applicable interpretation of the Staff, (ii) for any reason, the Exchange Offer is not consummated prior to the later of the date that is 270 days after the closing of the Merger or
90 days after the Outside Date or (iii) any Beneficial Owner of Registrable Securities notifies the Issuer that (A) it is prohibited by law or SEC policy from participating in the Exchange Offer, (B) it may not resell the Exchange
Securities acquired by it in the Exchange Offer to the public without delivering a prospectus and the prospectus contained in the Exchange Offer Registration 

  
 6 

 
Statement is not appropriate or available for such resales or (C) it is a broker-dealer and owns Securities acquired directly from the Issuer or an affiliate of the Issuer, then the Issuer
and the Guarantors shall promptly file after such determination date or notice is given to the Issuer, as the case may be, a Shelf Registration Statement providing for the sale by the Holders of all of the Registrable Securities and to use their
commercially reasonable efforts to cause the Shelf Registration Statement to be promptly declared effective by the SEC reasonably promptly but in any event on or prior to 90 days after the obligation to file such Shelf Registration Statement arises.
Notwithstanding the foregoing, in the event the Issuer and the Guarantors are required to file a Shelf Registration Statement solely as a result of the matters referred to in clause (iii)(B) of the preceding sentence, the Issuer and the Guarantors
shall use their commercially reasonable efforts to file and have declared effective by the SEC both an Exchange Offer Registration Statement pursuant to Section 2(a) above with respect to all Registrable Securities and a Shelf Registration
Statement (which may be combined with the Exchange Offer Registration Statement) with respect to offers and sales of Registrable Securities held by the Initial Purchasers after completion of the Exchange Offer. The Issuer and the Guarantors agree to
use their commercially reasonable efforts to keep the Shelf Registration Statement continuously effective for a period of at least one year following the date on which the obligation to file such Shelf Registration Statement arises (or such shorter
period that will terminate when all Securities covered by the Shelf Registration Statement have been sold pursuant to such Shelf Registration Statement). The Issuer and the Guarantors further agree to supplement or amend the Shelf Registration
Statement if required by the rules, regulations or instructions applicable to the registration form used by the Issuer for such Shelf Registration Statement or by the 1933 Act or by any other rules and regulations thereunder for shelf registration
or if reasonably requested by a Holder with respect to information relating to such Holder, and to use its commercially reasonable efforts to cause any such amendment to become effective and such Shelf Registration Statement to become usable as soon
as thereafter practicable. The Issuer and the Guarantors agree to furnish to the Holders of Registrable Securities copies of any such supplement or amendment promptly after its being used or filed with the SEC. 

(c) The Issuer and the Guarantors shall pay all Registration Expenses in connection with the registration pursuant to Section 2(a) and
Section 2(b) hereof. Each Holder shall pay all underwriting discounts and commissions and transfer taxes, if any, relating to the sale or disposition of such Holder’s Registrable Securities pursuant to the Shelf Registration Statement.

 (d) An Exchange Offer Registration Statement pursuant to Section 2(a) hereof or a Shelf Registration Statement pursuant to
Section 2(b) hereof will not be deemed to have become effective unless it has been declared effective by the SEC; provided, however, that, if, after it has been declared effective, the offering of Registrable Securities of any
series pursuant to a Shelf Registration Statement is interfered with by any stop order, injunction or other order or requirement of the SEC or any other governmental agency or court, such Registration Statement will be deemed not to have become
effective during the period of such interference with respect to such series of Registrable Securities until the offering of Registrable Securities of such series pursuant to such Registration Statement may legally resume. In the event (1) the
Issuer fails to consummate the Exchange Offer on or prior to the later of the date that is 270 days after the closing of the Merger or 90 days after the Outside Date (if the Exchange Offer is then required to be made), (2) if we are obligated
to file the Shelf Registration Statement, the Shelf Registration Statement is not declared effective by the SEC on or prior to the later of the date that is 270 days after the closing of the Merger or 90 days after the Outside Date, or (3) the
Shelf Registration Statement or 

  
 7 

 
the Exchange Offer Registration Statement is declared effective with respect to a series of Registrable Securities but thereafter ceases to be effective or usable in connection with resales or
exchanges of such series of Registrable Securities during the periods specified in this Agreement (each such event referred to in clauses (1), (2) and (3) above, a “Registration Default”), then with respect to the first
90-day period immediately following the occurrence of the first Registration Default, the interest rate on the Securities of such series will be increased by 0.25% per annum on the principal amount of Securities of such series held by such
Holder (such additional interest, the “Additional Interest”). The amount of Additional Interest will increase by an additional 0.25% per annum on the principal amount of Securities of such series with respect to each following
90-day period until all Registration Defaults have been cured, up to a maximum amount of Additional Interest for all Registration Defaults of 1.00% per annum. 

All accrued Additional Interest will be paid by the Issuer or the Guarantors on each interest payment date to the Holder of a global note by wire transfer of
immediately available funds or by federal funds check and to Holders of certificated notes by wire transfer to the accounts specified by them or by mailing checks to their registered addresses if no such accounts have been specified. 

Following the cure of all Registration Defaults, the accrual of Additional Interest will cease. 

(e) Without limiting the remedies available to the Initial Purchasers and the Holders, the Issuer and the Guarantors acknowledge that any
failure by the Issuer or the Guarantors to comply with their obligations under Section 2(a) and Section 2(b) hereof may result in material irreparable injury to the Initial Purchasers or the Holders for which there is no adequate remedy at
law, that it will not be possible to measure damages for such injuries precisely and that, in the event of any such failure, the Initial Purchasers or any Holder may obtain such relief as may be required to specifically enforce the obligations of
the Issuer and the Guarantors under Section 2(a) and Section 2(b) hereof. 
 3. Registration Procedures. 

In connection with the obligations of the Issuer and the Guarantors with respect to the Registration Statements pursuant to Section 2(a)
and Section 2(b) hereof, the Issuer and the Guarantors shall, within the timeframes specified hereunder: 
 (a) prepare and file with
the SEC a Registration Statement on the appropriate form under the 1933 Act, which form (x) shall be selected by the Issuer and (y) shall, in the case of a Shelf Registration, be available for the sale of the Registrable Securities by the
selling Holders thereof and (z) shall comply as to form in all material respects with the requirements of the applicable form and include all financial statements required by the SEC to be filed therewith, and use its commercially reasonable
efforts to cause such Registration Statement to become effective and remain effective in accordance with Section 2 hereof; 
 (b)
prepare and file with the SEC such amendments and post-effective amendments to each Registration Statement as may be necessary to keep such Registration Statement effective for the applicable period and cause each Prospectus to be supplemented by
any required prospectus supplement and, as so supplemented, to be filed pursuant to Rule 424 

  
 8 

 
under the 1933 Act; to keep each Prospectus current during the period described under Section 4(3) and Rule 174 under the 1933 Act that is applicable to transactions by brokers or dealers
with respect to the Registrable Securities or Exchange Securities; provided, however, that the Issuer may delay preparing, filing and distributing any such supplements or amendments (and continue the suspension of the use of the
Prospectus) if it would require disclosure of any event if (x) the Issuer determines in its good faith judgment that the disclosure of such event at such time would have a material adverse effect on the business, operations or prospects of the
Issuer or (y) the disclosure otherwise relates to a material business transaction or development which has not been publicly disclosed; provided, further, that (i) neither any such delay nor any such suspension shall extend
for a period of more than 30 days in any three-month period or a total of more than 75 days for all such periods in any twelve-month period (including in such total the period of all delays and suspensions pursuant to this clause (b), suspensions,
if any, of any disposition of Registrable Securities pursuant to a Registration Statement and all suspensions, if any, of effectiveness of a Registration Statement pursuant to any other provision of this Section 3) and shall not affect the
Issuer’s obligations to pay Additional Interest as contemplated by Section 2(d) hereof and (ii) the Issuer shall extend the period during which a Registration Statement shall be maintained effective pursuant to this Agreement by the
total number of days included in delays or suspensions pursuant to this clause (b), if any; 
 (c) in the case of a Shelf Registration,
furnish to each Holder of Registrable Securities, to counsel for the Initial Purchasers, to counsel for the Holders and to each Underwriter of an Underwritten Offering of Registrable Securities, if any, without charge, as many copies of each
Prospectus, including each preliminary Prospectus, and any amendment or supplement thereto and such other documents as such Holder or Underwriter may reasonably request, in order to facilitate the public sale or other disposition of the Registrable
Securities; and the Issuer consents to the use of such Prospectus and any amendment or supplement thereto in accordance with applicable law by each of the selling Holders of Registrable Securities and any such Underwriters in connection with the
offering and sale of the Registrable Securities covered by and in the manner described in such Prospectus or any amendment or supplement thereto in accordance with applicable law; 

(d) use its commercially reasonable efforts to register or qualify the Registrable Securities under all applicable state securities or
“blue sky” laws of such jurisdictions as any Holder of Registrable Securities covered by a Registration Statement shall reasonably request in writing by the time the applicable Registration Statement is declared effective by the SEC, to
cooperate with such Holders in connection with any filings required to be made with the Financial Industry Regulatory Authority and do any and all other acts and things which may be reasonably necessary or advisable to enable such Holder to
consummate the disposition in each such jurisdiction of such Registrable Securities owned by such Holder; provided, however, that the Issuer shall not be required to (i) qualify as a foreign corporation or as a dealer in
securities in any jurisdiction where it would not otherwise be required to qualify but for this Section 3(d), (ii) file any general consent to service of process or (iii) subject itself to taxation in any such jurisdiction if it is
not so subject; 

  
 9 

 (e) in the case of a Shelf Registration, notify each Holder of Registrable Securities, counsel
for the Holders and counsel for the Initial Purchasers promptly and, if requested by any such Holder or counsel, confirm such advice in writing (i) when a Registration Statement has become effective and when any post-effective amendment thereto
has been filed and becomes effective, (ii) of any request by the SEC or any state securities authority for amendments and supplements to a Registration Statement and Prospectus or for additional information after the Registration Statement has
become effective, (iii) of the issuance by the SEC or any state securities authority of any stop order suspending the effectiveness of a Registration Statement or the initiation of any proceedings for that purpose, (iv) if, between the
effective date of a Registration Statement and the closing of any sale of Registrable Securities covered thereby, the representations and warranties of the Issuer contained in any underwriting agreement, securities sales agreement or other similar
agreement, if any, relating to the offering cease to be true and correct in all material respects or if the Issuer receives any notification with respect to the suspension of the qualification of the Registrable Securities for sale in any
jurisdiction or the initiation of any proceeding for such purpose, (v) of the happening of any event during the period a Shelf Registration Statement is effective which makes any statement made in such Registration Statement or the related
Prospectus untrue in any material respect or which requires the making of any changes in such Registration Statement or Prospectus in order to make the statements therein not misleading and (vi) of any determination by the Issuer that a
post-effective amendment to a Registration Statement would be appropriate; 
 (f) make every reasonable effort to obtain the withdrawal of
any order suspending the effectiveness of a Registration Statement at the earliest possible moment and provide immediate notice to each Holder of the withdrawal of any such order; 

(g) in the case of a Shelf Registration, furnish to each Holder of Registrable Securities, without charge, at least one conformed copy of each
Registration Statement and any post-effective amendment thereto (without documents incorporated therein by reference or exhibits thereto, unless requested in writing); 

(h) in the case of a Shelf Registration, cooperate with the selling Holders of Registrable Securities to facilitate the timely preparation and
delivery of certificates representing Registrable Securities to be sold and not bearing any restrictive legends and enable such Registrable Securities to be in such denominations (consistent with the provisions of the Indenture) and registered in
such names as the selling Holders may reasonably request at least one business day prior to the closing of any sale of Registrable Securities; 

(i) (A) in the case of a Shelf Registration, upon the occurrence of any event contemplated by Section 3(e)(v) hereof, use its commercially
reasonable efforts to prepare and file with the SEC a supplement or post-effective amendment to a Registration Statement or the related Prospectus or any document incorporated therein by reference or file any other required document so that, as
thereafter delivered to the purchasers of the Registrable Securities, such Prospectus will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. The Issuer agrees to notify the Holders to suspend use of the Prospectus as promptly as practicable after the occurrence of such an event, and the Holders hereby agree to suspend use of the Prospectus
until the Issuer has amended or supplemented the Prospectus to correct such misstatement or omission; 

  
 10 

 (B) Notwithstanding clause (i)(A) above, if (i) any event contemplated by
Section 3(e)(v) hereof occurs and is continuing and (ii) (x) the Issuer determines in its good faith judgment that the disclosure of such event at such time would have a material adverse effect on the business, operations or prospects
of the Issuer or (y) the disclosure otherwise relates to a material business transaction or development which has not been publicly disclosed, the Issuer, upon providing notice to the Initial Purchasers and the Holders, may suspend the use of
the Prospectus included in any Shelf Registration Statement for periods of time not to exceed 30 consecutive days (each such period, a “Suspension Period”) and for no more than a total of 75 days during any 365-day period in which such suspensions are in effect (including in such total the period of all delays, if any, pursuant to Section 3(b) and all suspensions of any disposition of Registrable Securities
pursuant to a Registration Statement and all suspensions of effectiveness of a Registration Statement pursuant to any provision of this Section 3) and no Additional Interest pursuant to Section 2(d) shall accrue or be payable during any
such Suspension Period pursuant to this clause (B); provided, however, that upon the termination of any such Suspension Period, the Issuer shall promptly notify the Initial Purchasers and each Holder that such Suspension Period has
been terminated; provided, further, that no more than four Suspension Periods may be in effect in any 365-day period and the Issuer shall extend the period during which a Registration Statement shall be maintained effective pursuant to
this Agreement by the total number of days included in all Suspension Periods, if any. 
 (j) a reasonable time prior to the filing of any
Registration Statement, any Prospectus, any amendment to a Registration Statement or amendment or supplement to a Prospectus or any document which is to be incorporated by reference into a Registration Statement or a Prospectus after initial filing
of a Registration Statement, provide copies of such document to the Initial Purchasers and their counsel (and, in the case of a Shelf Registration Statement, the Holders and their counsel) and make such of the representatives of the Issuer, the
Guarantors or Actavis plc as shall be reasonably requested by the Initial Purchasers or their counsel (and, in the case of a Shelf Registration Statement, the Holders or their counsel) available for discussion of such document (other than with
respect to a document filed with the SEC pursuant to the 1934 Act that will be incorporated by reference in the Registration Statement or any Prospectus, in each case, that is not filed to correct a misstatement, an omission or noncompliance), and
shall not at any time file or make any amendment to the Registration Statement, any Prospectus or any amendment of or supplement to a Registration Statement or a Prospectus or any document which is to be incorporated by reference into a Registration
Statement or a Prospectus, of which the Initial Purchasers and their counsel (and, in the case of a Shelf Registration Statement, the Holders and their counsel) shall not have previously been advised and furnished a copy or to which the Initial
Purchasers or their counsel (and, in the case of a Shelf Registration Statement, the Holders or their counsel) shall reasonably object within three business days of receipt thereof; 

(k) obtain a CUSIP number for all Exchange Securities or Registrable Securities, as the case may be, not later than the effective date of a
Registration Statement; 

  
 11 

 (l) cause the Indenture to be qualified under the Trust Indenture Act of 1939, as amended (the
“TIA”), in connection with the registration of the Exchange Securities or Registrable Securities, as the case may be, cooperate with the Trustee and the Holders of each series to effect such changes to the Indenture as may be
required for the Indenture to be so qualified in accordance with the terms of the TIA and execute, and use its commercially reasonable efforts to cause the Trustee to execute, all documents as may be required to effect such changes and all other
forms and documents required to be filed with the SEC to enable the Indenture to be so qualified in a timely manner; 
 (m) in the case of a
Shelf Registration, make available for inspection by a representative of the Holders of the Registrable Securities, any Underwriter participating in any disposition pursuant to such Shelf Registration Statement, and attorneys and accountants
designated by the Holders, at reasonable times and in a reasonable manner, all financial and other records, pertinent documents and properties of the Issuer, and cause the officers, directors and employees of the Issuer to supply all information
reasonably requested by any such representative, Underwriter, attorney or accountant in connection with a Shelf Registration Statement; 

(n) [Reserved]; 
 (o) if
reasonably requested by any Holder of Registrable Securities covered by a Registration Statement, (i) promptly incorporate in a Prospectus supplement or post-effective amendment such information with respect to such Holder as such Holder
reasonably requests to be included therein and (ii) make all required filings of such Prospectus supplement or such post-effective amendment as soon as the Issuer has received notification of the matters to be incorporated in such filing;
provided, that the Issuer shall not be required to make more than three such filings on behalf of all Holders in any 30-day period; and 

(p) in the case of a Shelf Registration, enter into such customary agreements and take all such other actions in connection therewith
(including those requested by the Holders of a majority of the applicable series of the Registrable Securities being sold) in order to expedite or facilitate the disposition of such Registrable Securities including, but not limited to, an
Underwritten Offering and in such connection, (i) to the extent possible, make such representations and warranties to the Holders and any Underwriters of such Registrable Securities with respect to the business of the Issuer, the Guarantors and
Actavis plc and their respective subsidiaries, the Registration Statement, Prospectus and documents incorporated by reference or deemed incorporated by reference, if any, in each case, in form, substance and scope as are customarily made by issuers
to underwriters in underwritten offerings and confirm the same if and when requested, (ii) obtain opinions of counsel to the Issuer and the Guarantors (which counsel and opinions, in form, scope and substance, shall be reasonably satisfactory
to the Holders and such Underwriters and their respective counsel) addressed to each selling Holder and Underwriter of Registrable Securities, covering the matters customarily covered in opinions requested in underwritten offerings,
(iii) obtain “cold comfort” letters from the independent certified public accountants of the Issuer (and, if necessary, any other certified public accountant of any parent of the Issuer, or of any business acquired by the Issuer for
which financial 

  
 12 

 
statements and financial data are or are required to be included in the Registration Statement) addressed to each selling Holder and Underwriter of Registrable Securities, such letters to be in
customary form and covering matters of the type customarily covered in “cold comfort” letters in connection with underwritten offerings, and (iv) deliver such documents and certificates as may be reasonably requested by the Holders of
a majority in principal amount of the applicable series of the Registrable Securities being sold or the Underwriters, and which are customarily delivered in underwritten offerings, to evidence the continued validity of the representations and
warranties of the Issuer and the Guarantors made pursuant to clause (i) above and to evidence compliance with any customary conditions contained in an underwriting agreement. 

In the case of a Shelf Registration Statement, the Issuer may require each Holder of Registrable Securities to furnish to the Issuer such
information regarding the Holder and the proposed distribution by such Holder of such Registrable Securities as the Issuer may from time to time reasonably request in writing. 

In the case of a Shelf Registration Statement, each Holder agrees that, upon receipt of any notice from the Issuer of the happening of any
event of the kind described in Section 3(e)(v) hereof, such Holder will forthwith discontinue disposition of Registrable Securities pursuant to a Registration Statement until such Holder’s receipt of the copies of the supplemented or
amended Prospectus contemplated by Section 3(i) hereof, and, if so directed by the Issuer, such Holder will deliver to the Issuer (at its expense) all copies in its possession, other than permanent file copies then in such Holder’s
possession, of the Prospectus covering such Registrable Securities current at the time of receipt of such notice. If the Issuer shall give any such notice to suspend the disposition of Registrable Securities pursuant to a Registration Statement, the
Issuer shall extend the period during which the Registration Statement shall be maintained effective pursuant to this Agreement by the number of days during the period from and including the date of the giving of such notice to and including the
date when the Holders shall have received copies of the supplemented or amended Prospectus necessary to resume such dispositions. The Issuer, in total, may give any such notice only twice during any 365-day period and any such suspensions may not
exceed 30 days for each suspension and there may not be more than three suspensions in effect during any 365-day period. 
 The Holders of
Registrable Securities covered by a Shelf Registration Statement who desire to do so may sell such Registrable Securities in an Underwritten Offering. In any such Underwritten Offering, the investment banker or investment bankers and manager or
managers (the “Underwriters”) that will administer the offering will be selected by the Majority Holders of each series of the Registrable Securities included in such offering. 

4. Participation of Broker-Dealers in Exchange Offer. 

(a) The staff of the SEC (the “Staff”) has taken the position that any broker-dealer that receives Exchange Securities for
its own account in the Exchange Offer in exchange for Securities that were acquired by such broker-dealer as a result of market-making or other trading activities (a “Participating Broker-Dealer”), may be deemed to be an
“underwriter” within the meaning of the 1933 Act and must deliver a prospectus meeting the requirements of the 1933 Act in connection with any resale of such Exchange Securities. 

  
 13 

 The Issuer understands that it is the Staff’s position that if the Prospectus contained in
the Exchange Offer Registration Statement includes a plan of distribution containing a statement to the above effect and the means by which Participating Broker-Dealers may resell the Exchange Securities, without naming the Participating
Broker-Dealers or specifying the amount of Exchange Securities owned by them, such Prospectus may be delivered by Participating Broker-Dealers to satisfy their prospectus delivery obligation under the 1933 Act in connection with resales of Exchange
Securities for their own accounts, so long as the Prospectus otherwise meets the requirements of the 1933 Act. 
 (b) In light of the above,
notwithstanding the other provisions of this Agreement, the Issuer agrees that the provisions of this Agreement as they relate to a Shelf Registration shall also apply to an Exchange Offer Registration to the extent, and with such reasonable
modifications thereto as may be, reasonably requested by the Initial Purchasers or by one or more Participating Broker-Dealers, in each case as provided in clause (ii) below, in order to expedite or facilitate the disposition of any Exchange
Securities by Participating Broker-Dealers consistent with the positions of the Staff recited in Section 4(a) above; provided that: 

(i) the Issuer shall not be required to amend or supplement the Prospectus contained in the Exchange Offer Registration Statement, as would
otherwise be contemplated by Section 3(i) hereof, for a period exceeding 180 days after the last Exchange Date (as such period may be extended pursuant to Section 3 hereof) and Participating Broker-Dealers shall not be authorized by the
Issuer to deliver and shall not deliver such Prospectus after such period in connection with the resales contemplated by this Section 4; and 

(ii) the application of the Shelf Registration procedures set forth in Section 3 hereof to an Exchange Offer Registration, to the extent
not required by the positions of the Staff of the SEC or the 1933 Act and the rules and regulations thereunder, will be in conformity with the reasonable request to the Issuer by the Initial Purchasers or with the reasonable request in writing to
the Issuer by one or more broker-dealers who certify to the Initial Purchasers, on one hand, and the Issuer on the other hand, in writing that they anticipate that they will be Participating Broker-Dealers; and provided further that,
in connection with such application of the Shelf Registration procedures set forth in Section 3 hereof to an Exchange Offer Registration, the Issuer shall be obligated (x) to deal only with one entity representing the Participating
Broker-Dealers, which shall be the Representative unless it elects not to act as such representative, (y) to pay the fees and expenses of only one counsel representing the Participating Broker-Dealers, which shall be counsel to the Initial
Purchasers unless such counsel elects not to so act and (z) to cause to be delivered only one, if any, “cold comfort” letter from the independent certified public accountants of the Issuer (and, if necessary, one “cold
comfort” letter from each of the other certified public accountants of any parent of the Issuer, or of any business acquired by the Issuer for which financial statements and financial data are or are required to be included in the Registration
Statement) with respect to the Prospectus in the form existing on the last Exchange Date and with respect to each subsequent amendment or supplement, if any, effected during the period specified in clause (i) above. 

(c) The Initial Purchasers shall have no liability to the Issuer or any Holder with respect to any request that they may make pursuant to
Section 4(b) above. 

  
 14 

 5. Indemnification and Contribution. 

(a) Indemnification of the Initial Purchasers. Each of the Issuer and the Guarantors, jointly and severally, agrees to indemnify and
hold harmless each Initial Purchaser, each Holder and their respective directors, managers, general partner, officers, employees and agents and each person, if any, who controls any Initial Purchaser or any Holder within the meaning of the 1933 Act
and the 1934 Act, or is under common control with, or is controlled by, any Initial Purchaser or any Holder against any loss, claim, damage, liability or expense, as incurred, to which such Initial Purchaser, Holder or such director, managers,
general partner, officer, employee, agent or controlling person may become subject, under the 1933 Act, the 1934 Act or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if
such settlement is effected with the written consent of the Issuer), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon any untrue statement or alleged
untrue statement of a material fact contained in the Registration Statement, Prospectus or any Free Writing Prospectus (or any amendment or supplement thereto), or the omission or alleged omission therefrom of a material fact required to be stated
therein or necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and to reimburse each Initial Purchaser, Holder and each such director, manager, general partner, officer, employee,
agent and controlling person for any and all expenses (including the reasonable fees and disbursements of counsel chosen by the Representatives) as such expenses are reasonably incurred by such Initial Purchaser, Holder or such director, manager,
general partner, officer, employee, agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; provided, however, that the foregoing indemnity
agreement shall not apply to any loss, claim, damage, liability or expense to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and
in conformity with written information furnished to the Issuer by any Initial Purchaser through the Representatives or any selling Holder expressly for use in the Registration Statement, Prospectus or any Free Writing Prospectus (or any amendment or
supplement thereto). The indemnity agreement set forth in this Section 5(a) shall be in addition to any liabilities that the Issuer may otherwise have. 

(b) Indemnification of the Issuer, Guarantors and Directors and Officers. Each Holder agrees, severally and not jointly, to indemnify
and hold harmless the Issuer, each Guarantor, the Initial Purchasers, and the other selling Holders, each of their respective directors, managers or general partner who sign the Registration Statement and each person, if any, who controls the
Issuer, any Guarantor, any Initial Purchaser or any other selling Holder within the meaning of the 1933 Act or the 1934 Act, against any loss, claim, damage, liability or expense, as incurred, to which the Issuer, any Guarantor, any Initial
Purchaser or any other selling Holder or any such director, manager, general partner, officer or controlling person may become subject, under the 1933 Act, the 1934 Act, or other federal or state statutory law or regulation, or at common law or
otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Initial Purchaser), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below)
arises out of or is based upon any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, Prospectus or any Free Writing Prospectus (or any amendment or supplement thereto), or the

  
 15 

 
omission or alleged omission therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each
case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, Prospectus or any Free Writing Prospectus (or any amendment or supplement
thereto), in reliance upon and in conformity with written information furnished to the Issuer by such Holder expressly for use therein; and to reimburse the Issuer, any Guarantor, any Initial Purchaser or other selling Holder or any such director,
manager, general partner, officer or controlling person for any legal and other expense reasonably incurred by the Issuer, any Guarantor, any Initial Purchase or other selling Holder or any such director, manager, general partner, officer or
controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. 

(c) In case any proceeding (including any governmental investigation) shall be instituted involving any Person in respect of which indemnity
may be sought pursuant to either Section 5(a) or Section 5(b) above, such Person (the “indemnified party”) shall promptly notify the Person against whom such indemnity may be sought (the “indemnifying
party”) in writing and the indemnifying party, upon request of the indemnified party, shall retain counsel reasonably satisfactory to the indemnified party to represent the indemnified party and any others the indemnifying party may
designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel
shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have mutually agreed to the retention of such counsel or (ii) the named parties to any such proceeding (including any
impleaded parties) include both the indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is understood that the
indemnifying party shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for (a) the fees and expenses of more than one separate firm (in addition to any local counsel) for the Initial
Purchasers and all Persons, if any, who control any Initial Purchaser within the meaning of either Section 15 of the 1933 Act or Section 20 of the 1934 Act, (b) the fees and expenses of more than one separate firm (in addition to any
local counsel) for the Issuer and its directors and officers who sign the Registration Statement and each Person, if any, who controls the Issuer within the meaning of either such Section and (c) the fees and expenses of more than one separate
firm (in addition to any local counsel) for all Holders and all Persons, if any, who control any Holder within the meaning of either such Section, and that all such fees and expenses shall be reimbursed as they are incurred. In such case involving
the Initial Purchasers and Persons who control the Initial Purchasers, such firm shall be designated in writing by the Representative. In such case involving the Holders and such Persons who control Holders, such firm shall be designated in writing
by the Majority Holders. In all other cases, such firm shall be designated by the Issuer. The indemnifying party shall not be liable for any settlement of any proceeding effected without its written consent but, if settled with such consent or if
there be a final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an
indemnified party shall have requested an indemnifying party to reimburse the indemnified party for fees and expenses of counsel as contemplated by the second and third sentences of this paragraph, the indemnifying party agrees that it shall be
liable for any settlement of any 

  
 16 

 
proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii) such
indemnifying party shall not have reimbursed the indemnified party for such fees and expenses of counsel in accordance with such request prior to the date of such settlement. No indemnifying party shall, without the prior written consent of the
indemnified party, effect any settlement of any pending or threatened proceeding in respect of which such indemnified party is or could have been a party and indemnity could have been sought hereunder by such indemnified party, unless such
settlement includes an unconditional release of such indemnified party from all liability on claims that are the subject matter of such proceeding. 

(d) If the indemnification provided for in Section 5(a) or Section 5(b) above is unavailable to an indemnified party or insufficient
in respect of any losses, claims, damages or liabilities, then each indemnifying party under such paragraph, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by such indemnified party as a
result of such losses, claims, damages or liabilities in such proportion as is appropriate to reflect the relative fault of the indemnifying party or parties on the one hand and of the indemnified party or parties on the other hand in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative fault of the Issuer, on the one hand, and the Holders, on the other hand, shall be
determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Issuer, on the one hand, or by the
Holders, on the other hand, and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. The Holders’ respective obligations to contribute pursuant to this
Section 5(d) are several in proportion to the respective principal amount of Registrable Securities of such Holder that were registered pursuant to a Registration Statement. 

(e) The Issuer, on the one hand, and each Holder, on the other hand, agree that it would not be just or equitable if contribution pursuant to
this Section 5 were determined by pro rata allocation or by any other method of allocation that does not take account of the equitable considerations referred to in Section 5(d) above. The amount paid or payable by an
indemnified party as a result of the losses, claims, damages and liabilities referred to in Section 5(d) above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such
indemnified party in connection with investigating or defending any such action or claim. Notwithstanding the provisions of this Section 5, no Holder shall be required to indemnify or contribute any amount in excess of the amount by which the
total price at which Registrable Securities were sold by such Holder exceeds the amount of any damages that such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No
Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the 1933 Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. The remedies provided for in this
Section 5 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any indemnified party at law or in equity. 

The indemnity and contribution provisions contained in this Section 5 shall remain operative and in full force and effect regardless of
(i) any termination of this Agreement, (ii) any investigation made by or on behalf of the Initial Purchasers or any of their affiliates, any Holder or 

  
 17 

 
any Person controlling any Initial Purchaser or any Holder, or by or on behalf of the Issuer or its officers or directors or any Person controlling the Issuer, (iii) acceptance of any of the
Exchange Securities and (iv) any sale of Registrable Securities pursuant to a Shelf Registration Statement. 
 6. Miscellaneous.

 (a) No Inconsistent Agreements. The Issuer and each Guarantor represents, warrants and agrees that the Issuer or such Guarantor
has not entered into, and on or after the date of this Agreement will not enter into, any agreement which is inconsistent with the rights granted to the Holders of Registrable Securities in this Agreement or otherwise conflicts with the provisions
hereof. The Issuer and each Guarantor represents, warrants and agrees that the rights granted to the Holders hereunder do not and will not in any way conflict with and are and will not be not inconsistent with the rights granted to the holders of
the other issued and outstanding securities of the Issuer or such Guarantor under any such agreements. 
 (b) Amendments and Waivers.
With respect to any series of Securities, the provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or supplemented, and waivers or consents to departures from the provisions hereof may not be given
unless the Issuer has obtained the written consent of Holders of at least a majority in aggregate principal amount of the outstanding Registrable Securities of such series affected by such amendment, modification, supplement, waiver or consent;
provided, however, that no amendment, modification, supplement, waiver or consent to any departure from the provisions of Section 5 hereof shall be effective as against any Holder of Registrable Securities unless consented to in
writing by such Holder. 
 (c) Notices. All notices and other communications provided for or permitted hereunder shall be made in
writing by hand-delivery, registered first-class mail, telex, telecopier, electronic mail or any courier guaranteeing overnight delivery (i) if to a Holder, at the most current address given by such Holder to the Issuer by means of a notice
given in accordance with the provisions of this Section 6(c), which address initially is, with respect to the Initial Purchasers, the address set forth in the Purchase Agreement; and (ii) if to the Issuer, initially at the Issuer’s
address set forth in the Purchase Agreement and thereafter at such other address, notice of which is given in accordance with the provisions of this Section 6(c). 

All such notices and communications shall be deemed to have been duly given: at the time delivered by hand, if personally delivered; five
business days after being deposited in the mail, postage prepaid, if mailed; when answered back, if telexed; when receipt is acknowledged, if telecopied or emailed; and on the next business day if timely delivered to an air courier guaranteeing
overnight delivery. 
 Copies of all such notices, demands, or other communications shall be concurrently delivered by the Person giving the
same to the Trustee, at the address specified in the applicable Indenture. 
 (d) Successors and Assigns. This Agreement shall inure
to the benefit of and be binding upon the successors, assigns and transferees of each of the parties, including, without limitation and without the need for an express assignment, subsequent Holders; provided that

  
 18 

 
nothing herein shall be deemed to permit any assignment, transfer or other disposition of Registrable Securities in violation of the terms of the Purchase Agreement. If any transferee of any
Holder shall acquire Registrable Securities, in any manner, whether by operation of law or otherwise, such Registrable Securities shall be held subject to all of the terms of this Agreement, and by taking and holding such Registrable Securities such
Person shall be conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement and such Person shall be entitled to receive the benefits hereof. The Initial Purchasers (in their capacity as Initial
Purchasers) shall have no liability or obligation to the Issuer with respect to any failure by a Holder to comply with, or any breach by any Holder of, any of the obligations of such Holder under this Agreement. 

(e) Purchase and Sales of Securities. For so long as there are Registrable Securities outstanding, the Issuer and the Guarantors
(i) shall not resell any Securities that have been or will be acquired by them, and (ii) shall not permit any of their affiliates (as defined in Rule 144 under the 1933 Act) to resell any of the Securities that have been or will be
acquired by any of them other than (A) to the Issuer or (B) in compliance with the provisions of Rule 144 under the 1933 Act. 

(f) Third Party Beneficiary. The Holders shall be third party beneficiaries to the agreements made hereunder between the Issuer and the
Guarantors, on the one hand, and the Initial Purchasers, on the other hand, and shall have the right to enforce such agreements directly to the extent any Holder deems such enforcement necessary or advisable to protect its rights or the rights of
any other Holders hereunder. 
 (g) Counterparts. This Agreement may be executed in any number of counterparts and by the parties
hereto in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Delivery of an executed counterpart of a signature page to this Agreement
by telecopier, facsimile or other electronic transmission (e.g., a “pdf” or “tif”) shall be effective as delivery of a manually executed counterpart thereof. 

(h) Headings. The headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect the meaning
hereof. 
 (i) Governing Law. (a) This Agreement and any claim, controversy or dispute arising under or related to this
Agreement shall be governed by and construed in accordance with the internal laws of the State of New York. 
 (b) Consent to
Jurisdiction. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) may be instituted in the federal courts of the United States of
America located in the City and County of New York or the courts of the State of New York in each case located in the City and County of New York (collectively, the “Specified Courts”), and each party irrevocably submits to the
exclusive jurisdiction (except for suits, actions, or proceedings instituted in regard to the enforcement of a judgment of any Specified Court in a Related Proceeding (a “Related Judgment”), as to which such jurisdiction is
non-exclusive) of the Specified Courts in any Related Proceeding. Service of any process, summons, notice or document by mail to such party’s address 

  
 19 

 
set forth above shall be effective service of process for any Related Proceeding brought in any Specified Court. The parties irrevocably and unconditionally waive any objection to the laying
of venue of any Specified Proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any Specified Court that any Related Proceeding brought in any Specified Court has been brought in an
inconvenient forum. Each party not located in the United States irrevocably appoints CT Corporation System as its agent to receive service of process or other legal summons for purposes of any Related Proceeding that may be instituted in any
Specified Court. 
 (c) Judgment Currency. If for the purposes of obtaining judgment in any court it is necessary to convert a
sum due hereunder into any currency other than U.S. dollars, the parties hereto agree, to the fullest extent that they may effectively do so, that the rate of exchange used shall be the rate at which in accordance with normal banking procedures the
Initial Purchasers or Holder could purchase U.S. dollars with such other currency in The City of New York on the business day preceding that on which final judgment is given. The obligations of the Issuer and each Guarantor in respect of any
sum due from them to any Initial Purchaser or Holder shall, notwithstanding any judgment in any currency other than U.S. dollars, not be discharged until the first business day, following receipt by such Initial Purchaser of Holder of any sum
adjudged to be so due in such other currency, on which (and only to the extent that) such Initial Purchaser or Holder may in accordance with normal banking procedures purchase U.S. dollars with such other currency; if the U.S. dollars so purchased
are less than the sum originally due to such Initial Purchaser or Holder hereunder, the Issuer and each Guarantor agrees, as a separate obligation and notwithstanding any such judgment, to indemnify such Initial Purchaser or Holder against such
loss. If the U.S. dollars so purchased are greater than the sum originally due to such Initial Purchaser or Holder hereunder, such Initial Purchaser of Holder agrees to pay to the Issuer and the Guarantors (but without duplication) an
amount equal to the excess of the U.S. dollars so purchased over the sum originally due to such Initial Purchaser or Holder hereunder. 

(j) Entire Agreement; Severability. This Agreement contains the entire agreement between the parties relating to the subject matter
hereof and supersedes all oral statements and prior writings with respect thereto. In the event that any one or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable, the
validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby. 

[Remainder of page intentionally left blank] 

  
 20 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

					
	Very truly yours,
	
	ACTAVIS FUNDING SCS
	
	For and on behalf of Actavis International Holding S.à r.l., in its capacity as General Partner of Actavis Funding SCS, itself represented by:

		
	By:	 	 /s/ David A. Buchen

		 	Name:	 	David A. Buchen
		 	Title:	 	Class A Manager
	
	For and on behalf of Actavis International Holding S.à r.l., in its capacity as General Partner of Actavis Funding SCS, itself represented by:
		
	By:	 	 /s/ Patrick van Denzen

		 	Name:	 	Patrick van Denzen
		 	Title:	 	Class B Manager
	
	ACTAVIS CAPITAL S.À R.L., AS GUARANTOR
		
	By:	 	 /s/ David A. Buchen

		 	Name:	 	David A. Buchen
		 	Title:	 	Class A Manager
		
	By:	 	 /s/ Patrick van Denzen

		 	Name	 	: Patrick van Denzen
		 	Title:	 	Class B Manager

 [Signature Page to Registration Rights Agreement] 

 
					
	ACTAVIS, INC., AS GUARANTOR
		
	By:	 	 /s/ David A. Buchen

		 	Name:	 	David A. Buchen
		 	Title:	 	Chief Legal Officer – Global
	
	WARNER CHILCOTT LIMITED, AS GUARANTOR
		
	By:	 	 /s/ David A. Buchen

		 	Name:	 	David A. Buchen
		 	Title:	 	Chief Legal Officer – Global

 [Signature Page to Registration Rights Agreement] 

 The foregoing Agreement is hereby confirmed and accepted by the Representatives as of the date
first above written. 
  

			
	MERRILL LYNCH, PIERCE, FENNER & SMITH
	                              INCORPORATED
	MIZUHO SECURITIES USA INC.
	WELLS FARGO SECURITIES, LLC
	 Acting as Representatives of the several Initial Purchasers named in the attached Schedule A.

		
	By:	 	Merrill Lynch, Pierce, Fenner & Smith
		 	                     Incorporated
		
	By:	 	 /s/ Douglas Muller

	Name:	 	Douglas Muller
	Title:	 	Managing Director
		
	By:	 	Mizuho Securities USA Inc.
		
	By:	 	 /s/ Babak Ghatan

	Name:	 	Babak Ghatan
	Title:	 	Executive Director
		
	By:	 	Wells Fargo Securities, LLC
		
	By:	 	 /s/ Carolyn Hurley

	Name:	 	Carolyn Hurley
	Title:	 	Director

 [Signature Page to Registration Rights Agreement] 

 SCHEDULE A 

Merrill Lynch, Pierce, Fenner & Smith 

                     Incorporated 

Mizuho Securities USA Inc. 
 Wells Fargo Securities, LLC 

SMBC Nikko Securities America, Inc. 
 RBS Securities Inc. 

HSBC Securities (USA) Inc. 
 Mitsubishi UFJ Securities (USA), Inc.

 RBS Securities Inc. 
 SMBC Nikko Securities America, Inc.

 Deutsche Bank Securities Inc. 
 DnB NOR Markets, Inc. 

Lloyds Securities Inc. 
 TD Securities (USA) LLC 

Barclays Capital Inc. 
 Santander Investment Securities Inc. 

U.S. Bancorp Investments, Inc.EX-4.1

 Exhibit 4.1 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES LAWS, AND MAY
NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND ANY APPLICABLE
STATE SECURITIES LAWS. 
 Warrant No. [    ] 

WARRANT AGREEMENT 
 To
Purchase Shares of the Common Stock of 
 Cleveland BioLabs, Inc. 

Dated as of [            ] (the “Effective Date”) 

WHEREAS, Cleveland BioLabs, Inc., a Delaware corporation (the “Company”), has entered into a Securities Purchase Agreement of
even date herewith (the “Securities Purchase Agreement”) with, among others, [            ] (the “Warrantholder”); 

WHEREAS, pursuant to the Securities Purchase Agreement and as additional consideration to the Warrantholder for, among other things, its
investment in the Company’s Common Stock, the Company has agreed to issue to the Warrantholder this Warrant Agreement, evidencing the right to purchase shares of the Company’s Common Stock (this “Warrant” or this
“Agreement”); 
 NOW, THEREFORE, in consideration of the Warrantholder having executed and delivered the Securities
Purchase Agreement, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as follows: 

SECTION 1. GRANT OF THE RIGHT TO PURCHASE COMMON STOCK. 

(a) For value received, the Company hereby grants to the Warrantholder, and the Warrantholder is entitled, upon the terms and subject to
the conditions hereinafter set forth, to subscribe for and purchase, from the Company, up to such number of shares of Common Stock (as defined below) as determined in Section 1(b) below, at a purchase price per share equal to the Exercise Price
(as defined below). The number and Exercise Price of such shares are subject to adjustment as provided in Section 8. As used herein, the following terms shall have the following meanings: 

“Act” means the Securities Act of 1933, as amended. 

“Charter” means the Company’s Certificate of Incorporation or other constitutional document, as may be amended and in
effect from time to time. 

  
 1 

 “Common Stock” means the Company’s common stock, $0.005 par value per
share, as presently constituted under the Charter, and any class and/or series of Company capital stock for or into which such common stock may be converted or exchanged in a reorganization, recapitalization or similar transaction. 

“Exercise Price” means $0.56, subject to adjustment from time to time in accordance with the provisions of this Warrant. 

“Exercise Shares” shall mean the shares of the Company’s Common Stock issued or issuable upon exercise of this Warrant,
subject to adjustment pursuant to the terms herein, including, but not limited to, adjustment pursuant to Section 8 below. 

“Liquid Sale” means the closing of a Merger Event in which the consideration received by the Company and/or its stockholders,
as applicable, consists solely of cash and/or Marketable Securities. 
 “Marketable Securities” in connection with a Merger
Event means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the
“Exchange Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by
the Warrantholder in connection with the Merger Event were the Warrantholder to exercise this Warrant on or prior to the closing thereof is then traded on a national securities exchange or over-the-counter market, and (iii) the Warrantholder
would not be restricted by contract or by applicable federal and state securities laws from publicly re-selling, within six (6) months and one day following the closing of such Merger Event, all of the issuer’s shares and/or other
securities that would be received by the Warrantholder in such Merger Event were the Warrantholder to exercise this Warrant in full on or prior to the closing of such Merger Event. 

“Merger Event” means any of the following: (i) a sale, lease or other transfer of all or substantially all assets of the
Company, (ii) any merger or consolidation involving the Company in which the Company is not the surviving entity or in which the outstanding shares of the Company’s capital stock are otherwise converted into or exchanged for shares of
capital stock or other securities or property of another entity, or (iii) any sale by holders of the outstanding voting equity securities of the Company in a single transaction or series of related transactions of shares constituting a majority
of the outstanding combined voting power of the Company. 
 “Purchase Price” means, with respect to any exercise of this
Warrant, an amount equal to the then-effective Exercise Price multiplied by the number of shares of Common Stock as to which this Warrant is then exercised. 

(b) Number of Shares. This Warrant shall be exercisable for
[            ] shares of Common Stock, subject to adjustment from time to time in accordance with the provisions of this Warrant. 

  
 2 

 SECTION 2. TERM OF THE AGREEMENT. 

The term of this Agreement and the right to purchase Common Stock as granted herein shall commence on the Effective Date and shall be
exercisable for a period ending on the fifth (5th) anniversary of the Effective Date. 

SECTION 3. EXERCISE OF THE PURCHASE RIGHTS. 

(a) Exercise. The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any
time, or from time to time, prior to the expiration of the term set forth in Section 2 and in accordance with Section 3(b), by tendering to the Company at its principal office a notice of exercise in the form attached hereto as Exhibit I
(the “Notice of Exercise”), duly completed and executed. No ink-original Notice of Exercise shall be required, and provided that the shares of Common Stock are being issued in the name of the Warrantholder as written above, a
medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise Form shall not be required. Notwithstanding anything herein to the contrary, the Warrantholder shall not be required to physically surrender this Warrant to
the Company. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms set forth below (the “Exercise Shares Delivery Date”), the Company shall, as specified in the Notice of
Exercise, (i) no later than three (3) business days thereafter, issue to the Warrantholder a certificate for the number of shares of Common Stock purchased and deliver the certificate to an address in the United States as instructed by the
Warrantholder or (ii) no later than three (3) business days thereafter, cause the shares of Common Stock purchased to be made available to the Warrantholder via the Depository Trust Company’s Deposit or Withdrawal at Custodian
(“DWAC”) system if the shares are eligible for such transfer, or (iii) no later than seven (7) Trading Days thereafter, issue to the Warrantholder a certificate for the number of shares of Common Stock purchased and
deliver the certificate to an address in Russia as instructed by the Warrantholder. The Company shall also execute and deliver to the Warrantholder the acknowledgment of exercise in the form attached hereto as Exhibit II (the “Acknowledgment
of Exercise”) indicating the number of shares which remain subject to future purchases under this Warrant, if any. 
 (b) The
Purchase Price may be paid at the Warrantholder’s election either (i) by cash or check, or (ii) by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this Agreement and, if applicable, an
amended Agreement setting forth the remaining number of shares purchasable hereunder, in accordance with the formula set forth below (“Net Issuance”). If the Warrantholder exercises the Warrant by utilizing the Net Issuance method,
the Company will issue shares of Common Stock in accordance with the following formula: 
  

					
	         X = Y(A-B)

A     
	  	
			
	Where:	  	X =	  	the number of shares of Common Stock to be issued to the Warrantholder.
			
		  	Y =	  	the number of shares of Common Stock requested to be exercised under this Agreement.

  
 3 

					
			
	    	  	A =	  	the then-current fair market value of one (1) share of Common Stock at the time of exercise.
			
		  	B =	  	the then-effective Exercise Price.

 For purposes of the above calculation, the current fair market value of shares of Common Stock shall mean with
respect to each share of Common Stock: 
 (i) at all times when the Common Stock shall be traded on a national securities exchange,
inter-dealer quotation system or over-the-counter bulletin board service, the daily volume weighted average price of the Common Stock on the Trading Day immediately preceding the date on which the Warrantholder elects to exercise the Warrant;

 (ii) if the exercise is in connection with a Merger Event pursuant to Section 3(c) below, the per share value received by
the holders of the outstanding shares of Common Stock pursuant to the Merger Event as determined in accordance with the definitive transaction documents executed among the parties in connection with such Merger Event; or 

(iii) in cases other than as described in the foregoing clauses (i) and (ii), the current fair market value of a share of Common
Stock shall be determined in good faith by the Company’s Board of Directors. 
 Notwithstanding anything herein to the contrary,
on the Termination Date or if the exercise is in connection with a Merger Event, this Warrant shall be automatically exercised via cashless exercise pursuant to Section 3(b) or Section 3(c), as applicable. 

(c) Merger Event. In addition to any notice required pursuant to Section 8(d) below, the Company shall give Warrantholder at
least ten (10) business days’ written notice prior to consummating a Merger Event (the “Merger Event Notice”). To the extent this Warrant is not previously exercised as to all shares subject hereto, this Warrant shall be
deemed automatically exercised on a net exercise basis (even if not surrendered) as of immediately prior to the Merger Event pursuant to Section 3(b). The consideration per Warrant share distributable to the Warrantholder in connection such
Merger Event will consist of (a) if such Merger Event is a Liquid Sale, cash, cash equivalents or Marketable Securities (or any combination thereof) in an amount equal to the fair-market value of one share of Common Stock (determined in
accordance with Section 3(b)(ii)) minus the Exercise Price or (b) if the Merger Event is not a Liquid Sale, cash, cash equivalents, Marketable Securities, securities or other property (or any combination thereof) equal to the fair-market
value of one share of Common Stock (determined in accordance with Section 3(b)(ii)) minus the Exercise Price or (ii) if the then-current fair market value of one share of Common Stock (determined in accordance with Section 3(b)(ii))
is equal to or less than the Exercise Price then in effect, this Warrant shall be deemed to automatically expire (even if not surrendered) as of immediately prior to the Merger Event. 

(d) [Exercise Limitation. The Company shall not effect any exercise of this Warrant, and a Warrantholder shall not have the right
to exercise any portion of this Warrant, pursuant to Section 3 or otherwise, to the extent that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Warrantholder (together with the
Warrantholder’s 

  
 4 

 
affiliates, and any other persons acting as a group together with the Warrantholder or any of the Warrantholder’s affiliates), would beneficially own in excess of the Beneficial Ownership
Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Warrantholder and its affiliates shall include the number of shares of Common Stock issuable upon exercise of
this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by
the Warrantholder or any of its affiliates and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock equivalents) subject to a
limitation on conversion or exercise analogous to the limitation contained herein beneficially owned by the Warrantholder or any of its affiliates. Except as set forth in the preceding sentence, for purposes of this Section 3(d),
beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Warrantholder that the Company is not representing to the
Warrantholder that such calculation is in compliance with Section 13(d) of the Exchange Act and the Warrantholder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the limitation contained
in this Section 3(d) applies, the determination of whether this Warrant is exercisable (in relation to other securities owned by the Warrantholder together with any affiliates) and of which portion of this Warrant is exercisable shall be in the
sole discretion of the Warrantholder and the submission of a Notice of Exercise shall be deemed to be the Warrantholder’s determination of whether this Warrant is exercisable (in relation to other securities owned by the Warrantholder together
with any affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no
liability for exercise of the Warrant that are not in compliance with the Beneficial Ownership Limitation. In addition, a determination as to any group status as contemplated above shall be determined in accordance with Section 13(d) of the
Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section 3(d), in determining the number of outstanding shares of Common Stock, a Warrantholder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the
transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Warrantholder, the Company shall within two (2) business days confirm orally and in writing to the Warrantholder the
number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the
Warrantholder or its affiliates since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of
this Section 3(d) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or desirable to properly
give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant.] 

  
 5 

 (e) Compensation for Buy-In on Failure to Timely Deliver Warrant Shares Upon
Exercise. In addition to any other rights available to the Warrantholder, if the Company fails to cause its transfer agent to transmit to the Warrantholder the Exercise Shares on or before the Exercise Shares Delivery Date in accordance with the
Notice of Exercise pursuant to an exercise, and if after such date the Warrantholder is required by its broker to purchase (in an open market transaction or otherwise) or the Warrantholder’s brokerage firm otherwise purchases, shares of Common
Stock to deliver in satisfaction of a sale by the Warrantholder of the Warrant Shares which the Warrantholder anticipated receiving upon such exercise (a “Buy-In”), then the Company shall (A) pay in cash to the Warrantholder
the amount, if any, by which (x) the Warrantholder’s total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number of
Exercise Shares that the Company was required to deliver to the Warrantholder in connection with the exercise at issue times (2) the price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option
of the Warrantholder, either reinstate the portion of the Warrant and equivalent number of Exercise Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Warrantholder the number of
shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder. The Warrantholder shall provide the Company written notice indicating the amounts payable to the Warrantholder
in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Warrantholder’s right to any other remedies available to it hereunder, at law or in equity including, without
limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. 

SECTION 4. RESERVATION OF SHARES. 

During the term of this Agreement, the Company will at all times have authorized and reserved a sufficient number of shares of its Common Stock
to provide for the exercise of the rights to purchase Common Stock as provided for herein. 
 SECTION 5. NO FRACTIONAL SHARES OR SCRIP.

 No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this Agreement, but in lieu of such
fractional shares the Company shall make a cash payment therefor upon the basis of the Exercise Price then in effect. 
 SECTION 6. NO
RIGHTS AS STOCKHOLDER. 
 Without limitation of any provision hereof, Warrantholder agrees that this Agreement does not entitle the
Warrantholder to any voting rights or other rights as a stockholder of the Company prior to the exercise of any of the purchase rights set forth in this Agreement. 

  
 6 

 SECTION 7. WARRANTHOLDER REGISTRY. 

The Company shall maintain a registry showing the name and address of the registered holder of this Agreement. Warrantholder’s initial
address, for purposes of such registry, is set forth in Section 12(e) below. Warrantholder may change such address by giving written notice of such changed address to the Company. 

SECTION 8. ADJUSTMENT RIGHTS. 

The Exercise Price and the number of shares of Common Stock purchasable hereunder are subject to adjustment from time to time, as follows: 

(a) Reclassification of Shares. If the Company at any time shall, by combination, reclassification, exchange or subdivision of
securities or otherwise, change any of the securities as to which purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes of securities, this Agreement shall thereafter represent the
right to acquire such number and kind of securities as would have been issuable as the result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately prior to such combination,
reclassification, exchange, subdivision or other change. The provisions of this Section 8(a) shall similarly apply to successive combination, reclassification, exchange, subdivision or other change. 

(b) Subdivision or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the
case of a subdivision, the Exercise Price shall be proportionately decreased and the number of shares for which this Warrant is exercisable shall be proportionately increased, or (ii) in the case of a combination, the Exercise Price shall be
proportionately increased and the number of shares for which this Warrant is exercisable shall be proportionately decreased. 
 (c)
Stock Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall: 
 (i) pay a dividend
with respect to the outstanding shares of Common Stock payable in additional shares of Common Stock, then the Exercise Price shall be adjusted, to that price determined by multiplying the Exercise Price in effect immediately prior to such date of
determination by a fraction (A) the numerator of which shall be the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator of which shall be the total number of shares
of Common Stock outstanding immediately after such dividend or distribution, and the number of shares of Common Stock for which this Warrant is exercisable shall be proportionately increased; or 

(ii) make any other dividend or distribution on or with respect to Common Stock, except any dividend or distribution (A) in cash,
or (B) specifically provided for in any other clause of this Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon exercise or conversion of this Warrant a proportionate
share of any such distribution as though it were the holder of the Common Stock (or other stock for which the Common Stock is convertible) as of the record date fixed for the determination of the shareholders of the Company entitled to receive such
distribution. 

  
 7 

 (d) Notice of Certain Events. If: (i) the Company shall declare any dividend
or distribution upon its outstanding Common Stock, payable in stock, cash, property or other securities; (ii) the Company shall offer for subscription pro rata to the holders of its Common Stock any additional shares of stock of any class or
other rights; (iii) there shall be any Merger Event; or (iv) there shall be any voluntary dissolution, liquidation or winding up of the Company; then, in connection with each such event, the Company shall give the Warrantholder notice
thereof at the same time and in the same manner as it gives notice thereof to the holders of Common Stock. 
 SECTION 9. REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY. 
 (a) Reservation of Common Stock. The Company covenants and agrees that all
shares of Common Stock, if any, that may be issued upon the exercise of the rights represented by this Warrant will, upon issuance, be validly issued and outstanding, fully paid and non-assessable. The Company further covenants and agrees that the
Company will, at all times during the term hereof, have authorized and reserved, free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented by this Warrant. If at any time during
the term hereof the number of authorized but unissued shares of Common Stock shall not be sufficient to permit exercise of this Warrant in full, the Company will take such corporate action as may, in the opinion of its counsel, be necessary to
increase its authorized but unissued shares of Common Stock to such number of shares as shall be sufficient for such purposes. 
 (b)
Due Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock, have
been duly authorized by all necessary corporate action on the part of the Company. This Agreement: (1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation or order
applicable to it; and (3) except as could not reasonably be expected to have a Material Adverse Effect (as defined in the Securities Purchase Agreement), does not and will not contravene any provision of, or constitute a default under, any
indenture, mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid and binding agreement of the Company, enforceable in accordance with its terms, except as may be limited by
bankruptcy, insolvency, reorganization, moratorium or similar laws relating to or affecting creditors’ rights generally (including, without limitation, fraudulent conveyance laws) and by general principles of equity, regardless of whether
considered in a proceeding in equity or at law. 
 (c) Consents and Approvals. No consent or approval of, giving of notice to,
registration with, or taking of any other action in respect of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance by the Company of its obligations under this Agreement,
except for the filing of notices pursuant to Regulation D under the Act and any filing required by applicable state securities law, which filings will be effective by the time required thereby. 

  
 8 

 (d) Exempt Transaction. Subject to the accuracy of the Warrantholder’s
representations in Section 10, the issuance of the Common Stock upon exercise of this Agreement will constitute a transaction exempt from (i) the registration requirements of Section 5 of the Act, in reliance upon Section 4(2)
thereof, and (ii) the qualification requirements of the applicable state securities laws. 
 (e) Rule 144 Compliance.
Subject to the provisions included in the Registration Rights Agreement dated June 17, 2014, the Company shall, at all times prior to the earlier to occur of (x) the date of sale or other disposition by Warrantholder of this Warrant or all
shares of Common Stock issued on exercise of this Warrant, (y) the registration pursuant to the Registration Rights Agreement, or (z) the expiration or earlier termination of this Warrant if the Warrant has not been exercised in full or in
part on such date, use all commercially reasonable efforts to timely file all reports required under the 1934 Act and otherwise timely take all actions necessary to permit the Warrantholder to sell or otherwise dispose of this Warrant and the shares
of Common Stock issued on exercise hereof pursuant to Rule 144 promulgated under the Act as amended and in effect from time to time, provided that the foregoing shall not apply in the event of a Merger Event following which the successor or
surviving entity is not subject to the reporting requirements of the 1934 Act. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance with Rule 144, then, upon Warrantholder’s written
request to the Company, the Company shall furnish to the Warrantholder, within five (5) business days after receipt of such request, a written statement confirming the Company’s compliance with the filing and other requirements of such
Rule 144. 
 SECTION 10. REPRESENTATIONS AND COVENANTS OF THE WARRANTHOLDER. 

This Agreement has been entered into by the Company in reliance upon the following representations and covenants of the Warrantholder: 

(a) Investment Purpose. This Warrant and the shares issued on exercise hereof will be acquired for investment and not with a view
to the sale or distribution of any part thereof in violation of applicable federal and state securities laws, and the Warrantholder has no present intention of selling or engaging in any public distribution of the same except pursuant to a
registration or exemption. 
 (b) Private Issue. The Warrantholder understands (i) that the Common Stock issuable upon
exercise of this Agreement is not, as of the Effective Date, registered under the Act or qualified under applicable state securities laws, and (ii) that the Company’s reliance on exemption from such registration is predicated on the
representations set forth in this Section 10. 
 (c) Financial Risk. The Warrantholder has such knowledge and experience
in financial and business matters as to be capable of evaluating the merits and risks of its investment, and has the ability to bear the economic risks of its investment. 

(d) Accredited Investor. Warrantholder is an “accredited investor” within the meaning of Rule 501 of Regulation D
promulgated under the Act, as presently in effect, and Warrantholder is knowledgeable, sophisticated and experienced in making, and is qualified to 

  
 9 

 
make decisions with respect to, investments in shares presenting an investment decision like that involved in the purchase of the Common Stock and the Warrant, including investments in securities
issued by the Company and investments in comparable companies, and has requested, received, reviewed and considered all information it deemed relevant in making an informed decision to purchase the Warrant. 

SECTION 11. TRANSFERS. 

Subject to compliance with applicable federal and state securities laws, this Agreement and all rights hereunder are transferable, in whole or
in part, without charge to the holder hereof (except for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding the same, consents and agrees that this Agreement, when
endorsed in blank, shall be deemed negotiable, and that the holder hereof, when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the Company and all other persons dealing with this
Agreement as the absolute owner hereof for any purpose and as the person entitled to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company upon receipt by the Company of a
notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”), at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer. Until the
Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes. 
 SECTION 12.
MISCELLANEOUS 
 (a) Effective Date. The provisions of this Agreement shall be construed and shall be given effect in all
respects as if it had been executed and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company. 

(b) Remedies. In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights
either by suit in equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action for specific performance for any default where Warrantholder will not have an adequate remedy at
law and where damages will not be readily ascertainable. 
 (c) No Impairment of Rights. The Company will not, by amendment of
its Charter or through any other means, avoid or seek to avoid the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate in order to protect the rights of the Warrantholder against impairment. 
 (d)
Severability. In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable, the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or
unenforceable provision shall be replaced by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying the invalid, illegal or unenforceable provision. 

  
 10 

 (e) Notices. Except as otherwise provided herein, any notice, demand, request,
consent, approval, declaration, service of process or other communication that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly
served, given, delivered, and received upon the earlier of: (a) personal delivery to the party to be notified, (b) when sent by confirmed telex, electronic transmission or facsimile if sent during normal business hours of the recipient, if
not, then on the next business day, (c) five days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt, and shall be addressed to the party to be notified as follows: 
 If to
Warrantholder: 
 If to the Company: 

CLEVELAND BIOLABS, INC. 

Attention: Chief Executive Officer 

73 High Street 
 Buffalo, NY 14203

 Facsimile: 716-849-6820 

Telephone: 716-849-6810 
 Email:
Notices@cbiolabs.com 
 or to such other address as each party may designate for itself by like notice. 

(f) Entire Agreement; Amendments. This Agreement constitutes the entire agreement and understanding of the parties hereto in
respect of the subject matter hereof, and supersedes and replaces in their entirety any prior proposals, term sheets, letters, negotiations or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of
the terms of this Agreement may be amended except by an instrument executed by each of the parties hereto. 
 (g) Headings. The
various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of this Agreement or any provisions hereof. 

  
 11 

 (h) No Strict Construction. The parties hereto have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties hereto and no presumption or burden of proof shall arise
favoring or disfavoring any party by virtue of the authorship of any provisions of this Agreement. 
 (i) No Waiver. No
omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants or provisions hereof by Warrantholder at any time designated, shall be a waiver of any such right
or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions thereafter during the term of this Agreement. 

(j) Survival. All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant
hereto shall be for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination of this Agreement. 

(k) Governing Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be
governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Both party agree that all legal proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of Manhattan for the
adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives, and
agrees not to assert in any suit, action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such
party at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to
serve process in any other manner permitted by law. If either party shall commence an action, suit or proceeding to enforce any provisions of this Agreement, then the prevailing party in such action, suit or proceeding shall be reimbursed by the
other party for its reasonable attorneys’ fees and other costs and expenses incurred with the investigation, preparation and prosecution of such action or proceeding. 

(l) Counterparts. This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of
counterparts, and by different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which counterparts shall constitute but one and the same instrument. 

  
 12 

 (m) Lost, Stolen, Mutilated or Destroyed Warrant. If this Warrant is lost, stolen,
mutilated or destroyed, the Company may, on such terms as to indemnity or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and tenor as
this Warrant so lost, stolen, mutilated or destroyed. Any such new Warrant shall constitute an original contractual obligation of the Company, whether or not the allegedly lost, stolen, mutilated or destroyed Warrant shall be at any time enforceable
by anyone. 
 (n) Legends. To the extent required by applicable laws, this Warrant and the shares of Common Stock issuable
hereunder (and the securities issuable, directly or indirectly, upon conversion of such shares of Common Stock, if any) may be imprinted with a restricted securities legend in substantially the following form: 

THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR ANY APPLICABLE STATE SECURITIES
LAWS, AND MAY NOT BE SOLD, PLEDGED OR OTHERWISE TRANSFERRED WITHOUT AN EFFECTIVE REGISTRATION THEREOF UNDER THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR PURSUANT TO RULE 144 OR AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND
ANY APPLICABLE STATE SECURITIES LAWS. 
 (o) This Warrant has been made in Russian and English language. In the event of a conflict or
inconsistency between the English and Russian versions of the Warrant, the English version shall prevail. 
 [REMAINDER
OF PAGE INTENTIONALLY LEFT BLANK] 

  
 13 

 IN WITNESS WHEREOF, the parties hereto have caused this Warrant Agreement to be executed by its
officers thereunto duly authorized as of the Effective Date. 
  

			
	COMPANY:
	
	CLEVELAND BIOLABS, INC.
		
	By:	 	  

	Name:	 	Yakov Kogan, Ph.D., MBA
	Title:	 	Chief Executive Officer
	
	 WARRANTHOLDER:
  

  
 14 

 EXHIBIT I 

NOTICE OF EXERCISE 
 To:
                                         
                                

(1) The undersigned Warrantholder hereby elects to purchase [            ]
shares of the Common Stock of [                    ], pursuant to the terms of the Agreement dated the [    ] day of
[            ,             ] (the “Agreement”) between
[                    ] and the Warrantholder, and tenders herewith payment of the Purchase Price in full, together with all applicable transfer
taxes, if any. [NET ISSUANCE: elects pursuant to Section 3(b) of the Agreement to effect a Net Issuance.] 
 (2) Please issue a
certificate or certificates representing said shares of Common Stock in the name of the undersigned or in such other name as is specified below. 

(3) [Please make a book entry representing said shares of Common Stock in the name of the undersigned or in such other name as is
specified below and make such shares available pursuant to the attached instructions via the Depository Trust Company’s Deposit or Withdrawal at Custodian (“DWAC”) system.] 

 

			
	(Name)	 	 
		
	(Address)	 	 
	 	 	 
	
	WARRANTHOLDER:
		
	Name:	 	 
		
	Title:	 	 

  
 15 

 EXHIBIT II 

ACKNOWLEDGMENT OF EXERCISE 

The undersigned [                    ],
hereby acknowledge receipt of the “Notice of Exercise” from [                    ], to purchase
[            ] shares of the Common Stock of [                    ], pursuant to the
terms of the Agreement, and further acknowledges that [            ] shares remain subject to purchase under the terms of the Agreement. 

 

			
	COMPANY:
	
	CLEVELAND BIOLABS, INC.
		
	By:	 	  

	Name:	 	Yakov Kogan, Ph.D., MBA
	Title:	 	Chief Executive Officer
		
	Date:	 	  

  
 16 

 EXHIBIT III 

TRANSFER NOTICE 
 (To
transfer or assign the foregoing Agreement execute this form and supply required information. Do not use this form to purchase shares.) 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced thereby are hereby transferred and assigned to 

 
  

(Please Print) 
  

			
	whose address is	  	 

  
  

 

			
	Dated:	  	 

  

			
	Holder’s Signature:	  	 

  

			
	Holder’s Address:	  	 

  

			
	Signature Guaranteed:	  	 

  

	NOTE:	The signature to this Transfer Notice must correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever. Officers of corporations and those acting in a
fiduciary or other representative capacity should file proper evidence of authority to assign the foregoing Agreement. 

  
 17

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]